
Join to View Full Profile
209 MLK Jr WayTacoma, WA 98405
Phone+1 253-596-3300
Dr. Medepalli is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kantha Medepalli is a Pulmonary and Critical Care physician in Seattle, Wa. She received her medical degree from Northeast Ohio Medical University and has been in practice 8 years. She has 7 publications and 33 citings.
Education & Training
- University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 2014 - 2017
- Northeast Ohio Medical UniversityClass of 2014
- University of Miami/Jackson Health SystemFellowship, Pulmonary Disease and Critical Care Medicine
Certifications & Licensure
- WA State Medical License 2021 - 2026
- MA State Medical License 2020 - 2021
- OH State Medical License 2014 - 2018
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- 2 citationsAssociation of Women Leaders with Women Program Director and Trainee Representation Across US Academic Internal Medicine.Kantha Medepalli, Stefanie Purdon, Rebecca M Bade, M K Glassberg, Ellen L Burnham
Journal of General Internal Medicine. 2023-01-01 - 8 citationsTuberin Regulates Prostaglandin Receptor-mediated Viability, via Rheb, in mTORC1-hyperactive CellsChenggang Li, Xiaolei Liu, Yang Liu, Erik Zhang, Kantha Medepalli
Molecular Cancer Research. 2017-10-01 - Sequential Bronchoscopic Cryobiopsy and Cryotherapy.Lauryn A Benninger, Kantha Medepalli, Alejandro Aragaki-Nakahodo, Sadia Benzaquen, Philip Ong
Annals of the American Thoracic Society. 2017-06-01
Journal Articles
- Tuberin Regulates Prostaglandin Receptor–Mediated Viability, via Rheb, in mTORC1-Hyperactive CellsDarcy A Krueger, David N Franz, David J Kwiatkowski, Kantha Medepalli, Brian J Siroky, Jamie K Capal, Clinical Cancer Research
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: